Dosage Forms

Articles

FDA is expected to issue Emergency Use Authorization for Moderna’s vaccine, enabling immediate distribution.

FDA Advisors Recommend Moderna’s COVID-19 Vaccine

A newly developed polymer, DynaShield, may have the capability to ensure global access for COVID-19 treatment and prevention.

Helena Offers Polymer Solution to Global Cold Chain Issues for COVID-19 Vaccines, Biologics, and Therapeutics

The company has formed an agreement with the Ministry of Health of Singapore to supply mRNA-1273, Moderna’s COVID-19 vaccine candidate, to the people of Singapore. 

Moderna Enters into Supply Agreement to Provide Singapore with its COVID-19 Vaccine

The HERALD trial will involve participants 18 years and older who will receive a two-dose schedule of CVnCoV or placebo at multiple sites is Europe and Latin America.

CureVac Enrolls First Participant in COVID-19 Vaccine Candidate Trial 

EUA marks a milestone in COVID-19 vaccine development and is hailed as a turning point in pandemic fight. 

First COVID-19 Vaccine Heads to US Patients

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Success in combatting the pandemic depends on the ability of manufacturers to quickly and efficiently produce and distribute the huge quantities of vaccines demanded by the United States government and public health organizations around the world. 

Vaccine Scale-up and Production Key to Combatting Pandemic

Committee recommends Emergency Use Authorization of first mRNA-based COVID-19 vaccine; FDA approval is pending.

Pfizer-BioNTech Vaccine Moves Closer to EUA

Evonik offers lipid nanoparticles for gene-based drug development and manufacturing. 

Evonik Supplies Key LNP Technology for Gene-Based Drugs

The company has received $500 million in funding from Sino Biopharmaceutical for further development, capacity expansion, and manufacturing of CoronaVac, its COVID-19 vaccine candidate.

Sinovac Biotech Receives $500 Million in Funding for COVID-19 Vaccine Manufacturing  

CDMO HALIX will manufacture the drug substance for AstraZeneca’s COVID-19 vaccine candidate, AZD1222, at commercial scale at its cGMP facility in the Netherlands.